Particles that deliver vaccines directly to mucosal surfaces could defend against many infectious diseases.
Many viruses and bacteria infect humans through mucosal surfaces, such as those in the lungs, gastrointestinal tract and reproductive tract. To help fight these pathogens, scientists are working on vaccines that can establish a front line of defense at mucosal surfaces.
Vaccines can be delivered to the lungs via an aerosol spray, but the lungs often clear away the vaccine before it can provoke an immune response. To overcome that, MIT engineers have developed a new type of nanoparticle that protects the vaccine long enough to generate a strong immune response — not only in the lungs, but also in mucosal surfaces far from the vaccination site, such as the gastrointestinal and reproductive tracts.
Such vaccines could help protect against influenza and other respiratory viruses, or prevent sexually transmitted diseases such as HIV, herpes simplex virus and human papilloma virus, says Darrell Irvine, an MIT professor of materials science and engineering and biological engineering and the leader of the research team. He is also exploring use of the particles to deliver cancer vaccines.
“This is a good example of a project where the same technology can be applied in cancer and in infectious disease. It’s a platform technology to deliver a vaccine of interest,” says Irvine, who is a member of MIT’s Koch Institute for Integrative Cancer Research and the Ragon Institute of Massachusetts General Hospital, MIT and Harvard University.
Irvine and colleagues describe the nanoparticle vaccine in the Sept. 25 issue of Science Translational Medicine. Lead authors of the paper are recent PhD recipient Adrienne Li and former MIT postdoc James Moon.
Only a handful of mucosal vaccines have been approved for human use; the best-known example is the Sabin polio vaccine, which is given orally and absorbed in the digestive tract. There is also a flu vaccine delivered by nasal spray, and mucosal vaccines against cholera, rotavirus and typhoid fever.
To create better ways of delivering such vaccines, Irvine and his colleagues built upon a nanoparticle they developed two years ago. The protein fragments that make up the vaccine are encased in a sphere made of several layers of lipids that are chemically “stapled” to one another, making the particles more durable inside the body.
“It’s like going from a soap bubble to a rubber tire. You have something that’s chemically much more resistant to disassembly,” Irvine says.
This allows the particles to resist disintegration once they reach the lungs. With this sturdier packaging, the protein vaccine remains in the lungs long enough for immune cells lining the surface of the lungs to grab them and deliver them to T cells. Activating T cells is a critical step for the immune system to form a memory of the vaccine particles so it will be primed to respond again during an infection.
Stopping the spread of infection
In studies of mice, the researchers found that HIV or cancer antigens encapsulated in nanoparticles were taken up by immune cells much more successfully than vaccine delivered to the lungs or under the skin without being trapped in nanoparticles.
HIV does not infect mice, so to test the immune response generated by the vaccines, the researchers infected the mice with a version of the vaccinia virus that was engineered to produce the HIV protein delivered by the vaccine.
Mice vaccinated with nanoparticles were able to quickly contain the virus and prevent it from escaping the lungs. Vaccinia virus usually spreads to the ovaries soon after infection, but the researchers found that the vaccinia virus in the ovaries of mice vaccinated with nanoparticles was undetectable, while substantial viral concentrations were found in mice that received other forms of the vaccine.
Mice that received the nanoparticle vaccine lost a small amount of weight after infection but then fully recovered, whereas the viral challenge was 100 percent lethal to mice who received the non-nanoparticle vaccine.
“Giving the vaccine at the mucosal surface in the nanocapsule form allowed us to completely block that systemic infection,” Irvine says.
The Latest on: Nanoparticle vaccine
Scancell partnership with Cancer Research moves closer to clinic
on May 20, 2019 at 2:03 am
The nanoparticle technology utilised known lipid carriers that ... added that the organisation was pleased to see advances in the innovative vaccine, which could bring about urgently needed ... […]
Scancell and CRUK provide an update on SCIB2
on May 19, 2019 at 10:00 pm
The nanoparticle technology utilises known lipid carriers that ... "We're pleased to see advances in this innovative vaccine, which could bring about urgently needed improvements for some cancers. Our ... […]
Better Buy: Novavax vs. Inovio Pharmaceuticals
on May 18, 2019 at 9:00 am
The good news is that Novavax's fortunes don't depend entirely on ResVax. Nanoparticle-based influenza vaccine NanoFlu also has significant potential. Novavax announced positive phase 2 clinical study ... […]
Moderna Announces Publication of Preclinical Data for Chikungunya Antibody Program
on May 17, 2019 at 11:01 am
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation ... virus delivered in a proprietary lipid ... […]
Adenosine-Functionalized Biodegradable PLA-b-PEG Nanoparticles Ameliorate Osteoarthritis in Rats
on May 15, 2019 at 2:07 am
Biodegradable nanoparticles (NPs) have gained increasing interest for their ability to provide a viable carrier for delivery of vaccines, genes, drugs and other biomolecules. Their enhanced ... […]
Nanotech vaccine sheds light in fight against lethal virus
on May 14, 2019 at 4:00 am
Scientists at the University of Texas Medical Branch (UTMB), National Taiwan University (NTU) and Academia Sinica have developed a novel nanoparticle vaccine that mimics the morphology of MERS-CoV ... […]
OSU researcher to help lead $10.7 million push toward gonorrhea vaccine
on May 12, 2019 at 8:56 am
She’ll also be in charge of a project that will study incorporating antigens into nanoparticle platforms called nanodiscs, an attempt to increase vaccine potency and efficacy. In addition to OSU ... […]
SwRI, MBF Therapeutics sign exclusive license for proprietary drug delivery system
on May 9, 2019 at 10:14 am
Added, Dr. Lorraine Keller, CSO of MBFT, "SwRI's nanoparticles are the ideal delivery vehicles for our immunotherapeutic vaccines. Beyond this agreement, we look forward to working with SwRI on ... […]
Researching Advancements in Cancer Vaccines
on May 9, 2019 at 12:05 am
This vaccine has been developed for advanced prostate cancer ... the team was able to demonstrate that encapsulating an mRNA-encoding antigen with a certain nanoparticle triggered the effective ... […]
Vaccine design could dramatically improve cancer immunotherapies: study
on May 8, 2019 at 4:40 pm
The vaccine also protected the animals from reemerging tumors. The development of SNAs could be the breakthrough. SNAs are synthetic globular, rather than linear, forms of DNA and RNA that surround a ... […]
via Google News and Bing News